Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02160574 · ClinicalTrials.gov registry record · Phase 1
Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA
A Phase 1 study, sponsored by Zurex Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02160574 is a Phase 1 study that has completed, run by Zurex Pharma. The registered enrollment target is 40 participants.
The verdict
NCT02160574, a Phase 1 study, has completed, sponsored by Zurex Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a safety study to determine the cumulative skin irritation potential of ZuraPrep™ and ZuraPrep™ without Isopropyl Alcohol after repetitive patch applications to skin of human subjects.
Interventions
- DRUG ChloraPrep
- DRUG 0.1% Sodium Lauryl Sulfate
- DRUG 0.9% Physiological Saline
- OTHER ZuraPrep without IPA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02160574
The ClinicalTrials.gov registry entry for NCT02160574 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zurex Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ChloraPrep is the first listed.
NCT02160574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02160574 about?
NCT02160574 is a clinical study titled "Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA". This is a safety study to determine the cumulative skin irritation potential of ZuraPrep™ and ZuraPrep™ without Isopropyl Alcohol after repetitive patch applications to skin of human subjects.
What is the current status of trial NCT02160574?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-06. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02160574?
The interventions under investigation include: ChloraPrep (DRUG), 0.1% Sodium Lauryl Sulfate (DRUG), 0.9% Physiological Saline (DRUG), ZuraPrep without IPA (OTHER).
Who is sponsoring clinical trial NCT02160574?
This trial is sponsored by Zurex Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.